ImmutriX Therapeutics, Inc.

Advancing Blood Filtration Science

ImmutriX Therapeutics, Inc. is a privately funded medical technology company headquartered and incorporated in Rapid City, South Dakota, with a focused team of 19 employees. The company is developing innovative extracorporeal blood-filtration technologies designed to address urgent, unmet medical needs.

Our lead innovation is a proprietary hemoperfusion (HP) device – a “dialysis-like” procedure that directly removes harmful molecules from circulating blood while preserving essential blood components. Unlike traditional hemodialysis, which primarily clears small, water-soluble waste, hemoperfusion is uniquely capable of binding and eliminating larger, more complex toxins and inflammatory mediators that dialysis cannot effectively address.

ImmutriX research demonstrates that our engineered carbon materials can rapidly reduce toxins, poisons, and immune mediators from blood while preserving essential components such as platelets, albumin, and electrolytes. By targeting specific molecules that drive harmful immune responses—cytokines, chemokines, antigens, and antibodies—our technology can interrupt the pathological cascade that often leads to complications, organ failure, and death.

This advanced approach positions ImmutriX as a leader in next-generation, rapid-response therapies addressing acute, acute-on-chronic, and chronic medical conditions. By targeting critical unmet needs in emergency and intensive care, the technology establishes ImmutriX at the forefront of innovation—operating at the intersection of immunology, toxicology, and critical care medicine.

For more information, please contact ImmutriX Therapeutics, Inc.